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The preclinical safety and therapeutic eﬃcacy of adenoviral vectors that express the REIC/Dkk-3 
tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy.  The 
Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer eﬀects 
in vitro and in vivo,  and we herein report the results of two in vivo studies.  First,  intra-tumor 
Ad-hREIC administration was examined for toxicity and therapeutic eﬀects in a subcutaneous tumor 
model using the PC3 prostate cancer cell line.  Second,  intra-prostatic Ad-mREIC administration was 
tested for toxicity in normal mice.  The whole-body and spleen weights,  hematological and serum 
chemistry parameters,  and histological evaluation of tissues from throughout the body were analyzed.  
Both experiments indicated that there was no signiﬁcant diﬀerence in the examined parameters 
between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group.  In the in vitro 
analysis using PC3 cells,  a signiﬁcant apoptotic eﬀect was observed after Ad-hREIC treatment.  
Conﬁrming this observation,  the robust anti-tumor eﬃcacy of Ad-hREIC was demonstrated in the in 
vivo subcutaneous prostate cancer model.  Based on the results of these preclinical experiments,  we 
consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clini-
cal treatment of prostate cancer.
Key words: REIC,  Dickkopf-3,  gene therapy,  prostate cancer,  preclinical study
rostate cancer is a common and signiﬁcant dis-
ease in the male population of the United States 
and many other developed countries [1].  Cancer 
progression accelerates death in cancer patients,  and 
is often accompanied by a decrease in quality of life.  
The current therapeutic strategies,  such as androgen 
deprivation therapy,  radiation,  and cytotoxic chemo-
therapy,  often fail to stop the disease progression.  
Therefore,  novel and eﬀective therapies against pros-
tate cancer are urgently needed.
　 Cancer progression is often accompanied by the 
down-regulation of apoptosis [2] and the increased 
invasive and motile activity of the cancer cells [3].  
Cancer cells modulate the apoptotic and metastatic 
processes by producing both positive and negative 
eﬀectors [4,  5].  REIC/Dkk-3,  a member of the 
Dickkopf (Dkk) gene family known to interfere with 
Wnt signaling via Wnt receptors [6,  7],  was previ-
ously reported to play a distinct role in the induction 
of apoptosis and inhibition of metastasis [8,  9].  
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REIC/Dkk-3 induced robust anti-tumor eﬀects in vivo 
and cancer-speciﬁc apoptosis in a variety of cancer 
types when expressed by adenovirus-mediated gene 
transfer [8-13].  Moreover,  our recent study dis-
closed that the REIC/Dkk-3 protein also has a role in 
monocyte diﬀerentiation and tumor regression [14].  
Intratumoral administration of the REIC/Dkk-3 pro-
tein signiﬁcantly suppressed tumor growth,  with 
CD11c＋ and CD8＋ (dendritic and killer T cell marker,  
respectively) cell accumulation,  and enhanced the anti-
cancer cytolytic activity of splenocytes.  These data 
indicated a cytokine-like role of the REIC/Dkk-3 
protein in monocyte diﬀerentiation that might be 
exploited therapeutically.
　 Gene therapy has been applied to treat human dis-
eases in clinical trials and is considered to have thera-
peutic potential.  Our group has previously demon-
strated the feasibility of using adenoviral vectors for 
the treatment of prostate cancer in the clinic [15].  
Based on the background information noted above,  we 
are promoting the translation of in situ REIC/Dkk-3 
gene therapy from the lab to the clinic for patients 
with prostate cancer.  To perform the necessary pre-
clinical study as part of the progression to clinical use 
of the strategy,  we herein examined the toxicity and 
therapeutic eﬀects of the adenoviral vectors encoding 
the novel tumor suppressor REIC/Dkk-3.
Materials and Methods
　 Experimental animals. We used adult male 
mice (C57BL/6: 30-39g,  BALB/C nu/nu: 24-31g) 
to evaluate the toxicity and therapeutic eﬃcacy of the 
treatment strategy of using adenoviral vectors for the 
treatment of prostate cancer.  The mice were purchased 
from Japan SLC,  Inc.  (Hamamatsu,  Japan) and main-
tained in a speciﬁc pathogen-free environment with 
free access to food and water at the laboratory animal 
center of Okayama University.  They were allowed to 
adapt to their environment for more than one week 
before beginning the experiments.  The animals were 
housed and handled in accordance with the Okayama 
University Animal Research Committee Guidelines.
　 Adenovirus vector carrying REIC/Dkk-3 
(Ad-REIC). The full-length cDNA of mouse or 
human REIC/Dkk-3 was integrated into the cosmid 
vector,  pAxCAwt,  and then transferred into an aden-
oviral vector by the COS-TPC method (Takara Bio,  
Shiga,  Japan) [8].  An adenoviral vector carrying the 
LacZ gene (Ad-LacZ) was used as a control.  The 
adenoviral vectors are a replication-defective adenovi-
rus of serotype 5 that contain the indicated gene under 
the control of the CMV early enhancer/chicken β 
actin (CAG) promoter.  For the Ad-human REIC,  in 
vivo transduction ability after intratumoral vector 
injection was conﬁrmed by detecting the REIC protein 
expression [14].
　 Treatment protocol. The experimental design 
and doses of virus administered are shown in Fig.  1.  
The ﬁrst experiment was done using the prostate 
tumor mouse model.  To generate this model,  PC3 
human prostate cancer cells (2.5×106 in 50µl phos-
phate buﬀered saline (PBS)) were subcutaneously 
injected into the right thigh of BALB/C nu/nu mice.  
The tumors were permitted to grow to approximately 
5mm in diameter.  The mice were then randomly 
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Fig. 1　 The experimental design of the preclinical study is shown.  Toxicological analysis of mice administered Ad-hREIC and Ad-mREIC 
was performed in both experiment 1 and 2 using the indicated mouse models.  A study of the eﬃcacy of intratumoral administration of 
Ad-hREIC in a subcutaneous PC3 prostate cancer model was performed in experiment 1.
assigned into the treatment group with (1) intratu-
moral injection of Ad-LacZ,  (2) intratumoral injection 
of Ad-human REIC (Ad-hREIC) at the dose of 5×
1010 viral particles/tumor in 50µl buﬀer,  or (3) intra-
tumoral injection of 50µl PBS.  The selection of the 
dose was based on previous clinical studies of prostate 
cancer gene therapy in which adenovirus-mediated 
gene delivery was performed using a dose between 
1010 and 1011 viral particles/prostate [16-18].  The 
injections were targeted to the center and periphery of 
each mass to deliver the agent diﬀusely.  The size of 
the tumor was measured with vernier calipers until 25 
days after each treatment.  Tumor volume was calcu-
lated using the following formula: 1/2× (the shortest 
diameter)2× (the longest diameter).  In the second 
experiment,  the same number of Ad-mouse REIC 
(Ad-mREIC) viral particles in 50µl buﬀer was inocu-
lated into the bilateral lobes of the dorsolateral pros-
tate in normal C57BL/6 mice without any tumors.
　 The body weight of each mouse was monitored 
using a sensitive balance during the entire study 
period.  All the animals were observed daily for 
physical appearances,  activity levels,  and mortality 
patterns.  The ﬁrst day of vector administration was 
taken as Day 0,  while the day of sacriﬁce was desig-
nated as Day 32 and Day 21 in the ﬁrst and second 
experiments,  respectively.  In both experiments,  the 
spleen weight was measured at the time of sacriﬁce.  
For the histological analysis of the potential side 
eﬀects of the Ad-REIC treatment,  the dorsolateral 
prostate (the injection site) and selected organs (brain,  
lungs,  heart,  liver,  stomach,  spleen,  kidneys,  blad-
der,  and rectum) were dissected at the sacriﬁce of 
animals in the second experiment.  The tissues were 
then ﬁxed in formalin and embedded in paraﬃn sec-
tions.  The sections (5µm) were stained with hema-
toxylin and eosin and were examined for histopatho-
logical and cytotoxic changes.
　 Blood parameters. Blood was drawn from the 
inferior vena cava of each animal under deep anesthe-
sia with sodium pentobarbital.  The blood samples 
were collected in a plastic tube with ethylenedi-
aminetetra-acetic acid (EDTA).  The measurements of 
white blood cells (WBC),  hemoglobin,  hematocrit,  and 
platelets were carried out with the EDTA-treated 
anti-coagulated blood using a hematological instrument 
(MEK-6358,  Celltac-alpha,  Nihon Kohden,  Tokyo,  
Japan) within hours of collection.  To analyze the 
biochemical parameters,  we centrifuged the anti-
coagulated blood at 3,000 rpm for 10min,  and blood 
plasma was obtained and stored at －80℃.  Albumin 
concentrations were determined by the Bromo Cresol 
Green (BCG) assay,  using a commercially available 
kit (Wako Pure Chemical Industries Osaka,  Japan) 
and following the manufacturerʼs instructions.  The 
plasma levels of alanine aminotransferase (ALT),  
aspartate aminotransferase (AST),  alkaline phosphatase 
(ALP),  and lactate dehydrogenase (LDH) were deter-
mined by the JSCC transferable method by employing 
the standard ready-to-use kits (Wako Pure Chemical 
Industries).  Total bilirubin was evaluated by the azo-
bilirubin method,  using a commercial kit (Daiichi 
Pure Chemicals Co. Tokyo,  Japan).
　Western blotting analysis. The PC3 cells 
were washed twice with PBS and then lysed with lysis 
buﬀer (50mM HEPES,  pH7.4,  250mM NaCl,  1mM 
EDTA,  1ｵ NP-40,  1mM DTT,  1mM PMSF,  
5µg/ml leupeptin,  5µg/ml aprotinin,  2mM Na3VO4,  
1mM NaF,  10mM ß-GP),  and the proteins were 
extracted.  After centrifugation,  the supernatants 
were adjusted to achieve equal protein concentrations 
in each sample and then diluted with the same volume 
of 2×SDS sample buﬀer and heated for 5min at 
95℃.  Samples (10µg of protein) were separated on 
7.5ｵ SDS-PAGE gels and electroblotted onto a 
polyvinylidene ﬂuoride (PVDF) membrane.  The blots 
were blocked for 1h with 10ｵ nonfat milk powder,  
6ｵ Glycine,  and 0.1ｵ Tween-20 in Tris buﬀered 
saline (TBS) at room temperature.  The proteins were 
then identiﬁed with the use of the primary antibody,  a 
rabbit anti-human REIC/Dkk-3 polyclonal antibody 
raised in our laboratory [8] (1 : 1,000 dilution).  After 
extensive washing with 0.1ｵ Tween-20 in TBS 
(T-TBS),  the blots were exposed to the appropriate 
horseradish peroxidase-conjugated secondary antibody.  
After another round of extensive washing with T-TBS,  
membranes were developed using the enhanced chemi-
luminescence detection method (ECL kit,  Amersham 
Pharmacia Biotech,  Chandler,  AZ,  USA).
　 Apoptosis assay. To examine in vitro apoptosis 
induction after the treatments,  we seeded cells in ﬂat-
bottom 6-well plates and incubated them for 24h.  
The cells were then treated with Ad-LacZ and 
Ad-REIC at the indicated multiplicity of infection 
(MOI) in serum-free medium (500µl) for 2h,  and the 
medium was exchanged for fresh complete medium 
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(2ml).  After an additional 48h of incubation,  Hoechst 
33342 stock solution was added into the medium at a 
2µg/ml concentration,  and the cells were incubated in 
the dark for 10min.  Hoechst 33342 is an intercalating 
dye that allows the determination of variations in the 
total chromatin quantity and the degree of chromatin 
condensation [11].  Using ﬂuorescence microscopy,  we 
identiﬁed apoptotic cells by the presence of highly 
condensed or fragmented nuclei.  Apoptotic cells were 
counted at 5 diﬀerent ﬁelds under microscopic obser-
vation.  One hundred cells were judged under each 
ﬁeld.
　 Statistical analysis. The data are expressed 
as the means ± standard error (S.E.).  An unpaired 
Studentʼs t-test was performed for the statistical 
analysis between the 2 groups.  The diﬀerences were 
considered statistically signiﬁcant at p＜0.05.
Results
　 In the ﬁrst experiment,  we examined the in vivo 
toxicity and eﬃcacy of the Ad-hREIC vector using the 
subcutaneous human prostate tumor mouse xenograft 
model.  The experiment was designed as a preclinical 
study to support the future clinical use of Ad-hREIC,  
and we therefore evaluated its toxicological proﬁle and 
anti-tumor eﬀects.  We also conducted a second experi-
ment in non-tumor-bearing mice to examine the safety 
of Ad-mREIC,  to ensure that speciﬁcally overex-
pressing REIC/Dkk3 via intra-prostatic injection does 
not result in toxicity.
　 None of the mice died during the ﬁrst experiment 
in any of the treatment groups (n＝5).  In the second 
experiment,  1 or 2 mice died in each group during the 
experiment [PBS (n＝15): one mouse died on day 
18; Ad-LacZ (n＝16): 1 mouse each died on day 7 
and day 18; Ad-mREIC (n＝16): 1 mouse died on day 
18 and one on day 19].  At necropsy,  there was no 
obvious cause of death such as extensive inﬂammation,  
abnormal bladder distension,  trauma of various organs,  
or abundant ascites.
　 In both the ﬁrst and second experiments,  there was 
no statistically signiﬁcant diﬀerence in the survival 
between the Ad-REIC-treated group and the control 
groups by Mantel-Cox log-rank analysis (data not 
shown).  The physical appearances and activities were 
observed carefully,  and there were no deﬁnite diﬀer-
ences among the groups in either experiment.  
Inﬂammation-related ﬁndings such as abscesses were 
not detected at the time of sacriﬁce in any of the ani-
mals.  The time courses of body weight loss in both 
experiments are shown in Fig.  2A.  The average body 
weight at the start point was as follows: PBS 27.0g,  
Ad-LacZ 26.1g,  Ad-hREIC 29.3g in experiment 1 
and PBS 34.2g,  Ad-LacZ 34.3g,  Ad-mREIC 33.7g 
in experiment 2.  Although the average body weight of 
Ad-mREIC-treated mice tended to decrease more 
rapidly in experiment 2,  no signiﬁcant diﬀerence was 
observed in the body weight at any time point between 
the Ad-mREIC- and Ad-LacZ-treated groups.  The 
body weight change between pre-treatment and the 
time of sacriﬁce was calculated for each treatment 
group,  and no signiﬁcant changes were observed in any 
of the groups during either experiment (Fig.  2B).
　 To assess the systemic toxicology,  we collected 
blood and performed hematological (WBC,  hemoglo-
bin,  hematocrit,  and platelets) and plasma chemistry 
(albumin,  ALT,  AST,  ALP,  total bilirubin) evalua-
tions (Table 1).  There were no statistically signiﬁcant 
diﬀerences between the Ad-LacZ and Ad-REIC groups 
in any of the parameters for either experiment.  
Because the LDH levels were aﬀected by hemolysis of 
the collected blood samples,  the diﬀerences in LDH 
activity could not be attributed to the toxicity of 
Ad-REIC treatment (data not shown).
　 To conﬁrm the protein expression and apoptotic 
eﬀect induced by Ad-REIC,  we treated PC3 prostate 
cancer cells with Ad-hREIC.  A Western blotting 
analysis demonstrated signiﬁcant expression of the 
REIC/Dkk-3 protein in PC3 cells on day 2 after the 
treatment (Fig.  3A).  In an apoptosis assay using the 
Hoechst 33342 stain,  apoptotic cells were frequently 
observed in Ad-hREIC-treated PC3 cells (Fig.  3B,  
upper panel).  The mean rate of apoptosis at 10,  20,  
and 100 MOI was 13.7ｵ,  30.1ｵ,  and 67.5ｵ,  respec-
tively,  and signiﬁcant apoptotic induction was observed 
for each Ad-hREIC concentration in comparison to the 
control Ad-LacZ treatment (Fig.  3B,  lower panel).
　In the ﬁrst in vivo experiment,  we further demon-
strated the anti-tumor eﬀects of Ad-hREIC using a 
subcutaneous PC3 tumor model (Fig.  4).  In the PBS- 
and Ad-LacZ-treated groups,  the tumor size progres-
sively increased during the observation period.  In 
contrast,  the tumor growth in the Ad-REIC-treated 
group was signiﬁcantly suppressed.  In fact,  the tumor 
had macroscopically disappeared at the time of sacri-
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ﬁce in one of the mice in the Ad-hREIC-treated group.  
A statistically signiﬁcant reduction of the tumor vol-
ume was observed on days 21 and 25 in the Ad-REIC-
treated group compared to the Ad-LacZ group.
　 To further examine the systemic toxicology of the 
Ad-mREIC treatment,  we performed histological 
analyses using sections of the various organs (brain,  
lungs,  heart,  liver,  stomach,  spleen,  kidneys,  bladder,  
and rectum) in the second experiment.  There were no 
histopathological abnormalities in the observed sec-
tions in any of the treatment groups (data not shown).  
We also investigated the local eﬀects of Ad-mREIC 
injection by a histopathological analysis of the dorso-
lateral prostate,  the site where the vector was 
injected.  In the Ad-LacZ and Ad-mREIC treatment 
groups,  inﬁltration of mononuclear cells typical of 
lymphocytes was observed in the interstitial area (Fig.  
5A).  In the Ad-LacZ-injected prostate,  some degener-
ated prostatic glands containing fewer epithelial cells 
than normal were observed,  indicating cytotoxic 
changes after Ad-LacZ treatment.  Epithelial cell 
proliferation was also observed in the prostatic glands 
of the Ad-LacZ group,  indicating some degree of 
related inﬂammation.  We could not detect any histo-
logical eﬀects in the prostatic sections of the PBS-
treated group.
　 Because the REIC/Dkk-3 gene product is reported 
to possess immunological activity [14],  we also 
assessed the spleen weight to determine whether the 
treatment induces the side eﬀect of splenomegaly.  The 
spleen weight of each mouse was measured at the time 
of sacriﬁce in both in vivo experiments,  and there 
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Fig. 2　 A,  The mouse body weight is shown on the indicated days after each treatment.  Five to 9 mice were analyzed for each 
group; B,  The body weight changes between pre-treatment and the time of sacriﬁce are shown for each treatment group for experiments 
1 and 2.  Five to 9 mice were analyzed for each group.  No signiﬁcant (n.s.) diﬀerence was observed in any group in terms of body weight 
change.
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Fig. 3　 A,  REIC/Dkk-3 expression after Ad-LacZ and Ad-hREIC treatment at 100 MOI was examined in PC3 prostate cancer cells by 
Western blotting analysis.  The total protein was extracted on day 2 after the treatment,  and 10µg of protein was loaded per lane; B,  The 
induction of apoptosis after in vitro Ad-hREIC treatment was examined in PC3 cells by Hoechst 33342 staining.  The upper panel indicates 
the appearance of apoptotic cells after Ad-hREIC treatment.  The lower panel shows the apoptotic rate of PC3 cells after the indicated 
treatments.  A total of 5 diﬀerent ﬁelds were examined under a microscope to determine the apoptotic rate.  A signiﬁcant diﬀerence was 
observed (＊p＜0.05) between the Ad-hREIC and the control Ad-LacZ treatment.
Table 1　 The hematological (WBC,  hemoglobin,  hematocrit and platelets) and plasma chemistry (albumin,  ALT,  AST,  ALP,  total 
bilirubin) evaluations were performed with the blood samples collected at the time of sacriﬁce.  Shown are the means and standard errors 
of values for 4 to 5 animals per group.
 No.1
Treatment WBC Hemoglobin Hematocrit Platelets Alb ALT AST ALP Total Bilirubin
(102 cells/µl) (g/dl) (%) (104/µl) (g/dl) (IU/l) (IU/l) (IU/l) (mg/dl)
PBS 53.0±11.1 11.6±1.5 43.5±4.7 66.7±21.6 2.2±0.11 36.0±1.9 100.2±9.9 107.6±4.2 0.04±0.01
Ad-LacZ 71.0±5.8 10.2±0.5 38.7±1.8 98.3±9.0 2.1±0.10 36.6±1.4 102.8±13.1 76.6±7.4 0.03±0.00
Ad-hREIC 53.0±5.1 10.2±0.3 37.7±1.0 87.6±10.9 2.0±0.08 42.4±7.3 85.6±12.5 94.2±8.8 0.02±0.01
 No.2
Treatment WBC Hemoglobin Hematocrit Platelets Alb ALT AST ALP Total Bilirubin
(102 cells/µl) (g/dl) (%) (104/µl) (g/dl) (IU/l) (IU/l) (IU/l) (mg/dl)
PBS 50.5±7.4 9.6±0.2 35.4±0.7 75.6±16.6 2.2±0.05 44.8±26.5 52.8±18.9 124.8±2.9 0.03±0.00
Ad-LacZ 67.0±6.7 9.6±0.5 35.6±1.6 60.8±9.9 2.1±0.08 26.5±8.9 41.3±7.4 136.3±7.6 0.04±0.01
Ad-mREIC 69.5±9.6 9.6±0.9 35.7±3.0 73.9±14.8 1.9±0.05 42.3±19.0 47.5±11.2 125.3±2.9 0.03±0.00
WBC,  white blood cells; Alb,  Albumin; ALT,  alanine aminotransferase; AST,  aspartate aminotransferase; ALP,  alkaline phosphatase.
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Fig. 5　 A,  To examine the local eﬀects of Ad-mREIC treatment,  we performed histological analysis of the vector injection site during 
the second experiment.  The dorsolateral prostates (the injection site) were dissected at the time of sacriﬁce and ﬁxed in formalin.  The 
sections,  stained with hematoxylin and eosin,  were analyzed for histopathological and cytotoxic changes.  The asterisk shows a degener-
ated prostatic gland that contains fewer epithelial cells than normal.  The daggers indicate the aﬀected prostatic glands with epithelial cell 
proliferation.  The selected area (black square) is magniﬁed in the inset panel,  and the arrowhead indicates a mononuclear cell typical of 
lymphocytes; B,  To assess the eﬀects on the spleen after Ad-REIC treatment,  we measured the spleen weight of each mouse at the time 
of sacriﬁce in both experiments.  Four to 5 mice were analyzed for each group.  No signiﬁcant (n.s.) diﬀerence was observed in the spleens 
of any of the mice in any of the treatment groups.
Fig. 4　 The inhibitory eﬀect of the Ad-hREIC treatment on PC3 tumor growth in 
nude mice is indicated.  The left photograph shows the appearance of subcutane-
ous xenograft tumors at the time of sacriﬁce after treatment with PBS,  Ad-LacZ,  
and Ad-hREIC.  The tumor could not be detected macroscopically on the sacriﬁce 
of one mouse in the Ad-hREIC-treated group.  The mean volume of tumors was 
calculated for 5 mice of each group,  and the tumor growth curves are shown in the 
right panel.  A signiﬁcant diﬀerence (＊p＜0.05) was observed between the results 
of Ad-hREIC and the control Ad-LacZ treatment.
were no statistically signiﬁcant diﬀerences in spleen 
weight following treatment in either treatment group 
(Fig.  5B).
Discussion
　 We previously cloned the REIC (Reduced 
Expression in Immortalized Cells) gene and reported 
that its expression is down-regulated in a variety of 
cancer cell lines and tumors [8,  10-12,  19-21].  The 
REIC gene is identical to the Dickkopf-3 (Dkk-3) gene 
[20] and REIC/Dkk-3 seems to be one of the most 
innovative tumor suppressor genes used for cancer 
gene therapy [8,  9,  12,  21].  We have extensively 
utilized an adenoviral vector agent,  Ad-hREIC,  con-
taining the human REIC/Dkk-3 gene under the control 
of the CAG promoter in preclinical cancer models in 
mice.  The adenoviral vector carrying human REIC/
Dkk-3 selectively induced apoptosis in prostate cancer 
and malignant mesothelioma cells through the activa-
tion of c-Jun-NH2-kinase (JNK) and c-Jun [8,  12].  
The adenovirus-mediated expression of the REIC/
Dkk-3 gene eﬃciantly induces endoplasmic reticulum 
(ER) stress-mediated apoptosis in a cancer cell-spe-
ciﬁc manner [12,  13].  The current study also demon-
strated that the Ad-hREIC treatment induced signiﬁ-
cant apoptosis in a prostate cancer cell line.  We 
further demonstrated the robust therapeutic utility of 
Ad-hREIC in a subcutaneous prostate cancer model.  
Thus,  the adenoviral agent appears to be eﬀective 
against human prostate tumors in terms of the cancer-
speciﬁc targeting and a more radical response to 
expression of the gene.
　 The therapeutic eﬀects of Ad-REIC were previ-
ously observed in a variety of in vivo tumor models 
generated with prostate,  breast,  and mesothelioma 
cancer cells [8,  9,  11,  12],  but the toxicity of the 
Ad-REIC treatment remained unknown.  Thus,  we 
currently focused on the safety of local injection of 
Ad-REIC for the treatment of prostate cancer.  Non-
human primates have been used in some studies of 
adenoviral vector toxicity [22,  23],  and mice have 
many advantages for preclinical evaluations prior to 
these primate studies [24].  To evaluate the toxicity 
of the Ad-REIC vector,  we ﬁrst analyzed the lethality 
and survival in 2 experiments.  There was no toxicity 
when tumor-bearing mice were administered the human-
REIC vector,  although some lethality was observed in 
the mice during the second experiment.  However,  
since the survival was not statistically diﬀerent 
between the groups (1 or 2 mice died in both the con-
trol and treatment groups),  it is likely that the 
Ad-REIC treatment itself did not speciﬁcally induce 
the deaths.  The most conceivable reason for the 
lethality is that the mice in the second experiment died 
due to post-operative complications of the open sur-
gery for the prostatic injections.  The other possibility 
is that adenovirus toxicity may be the cause of the 
deaths.  Although deﬁnite histological damage was not 
observed in the examined mice,  we cannot exclude this 
possibility.  To conﬁrm the reproducibility of the 
deaths and to exclude the adenovirus-related death,  we 
did similar additional experiments using C57BL/6 
mice in which there was no death during the experi-
mental schedule until day 28.  Thus,  it seems that the 
death in experiment 2 was not reproducible and not 
adenovirus-related.  Based on these results,  another 
possibility is that the mice deaths may have been 
procedure-related.
　 We next investigated the systemic toxicity of the 
Ad-REIC treatment.  The liver has been widely recog-
nized as the primary target organ of adenoviral vec-
tors after an intravenous adenoviral administration 
[25].  Although the Ad-REIC was locally adminis-
tered by intratumoral or intra-prostate injection in our 
experiments,  the possibility could not be excluded that 
the viral particles might disseminate into the general 
circulation and aﬀect the liver functions.  However,  in 
the current studies using Ad-hREIC and Ad-mREIC,  
we did not detect any diﬀerences in the liver enzymes 
or other biochemical parameters in any of the 3 treat-
ment groups.  None of the mice showed histopatho-
logical liver abnormalities such as cytotoxicity or 
inﬂammation in the PBS-,  Ad-LacZ-,  or Ad-mREIC-
treated groups during the second experiment (data not 
shown),  indicating the consistency of the results of 
biochemical evaluations.  As for other distant organs,  
no histological abnormalities were observed (data not 
shown) in the screening,  although there were some 
histological changes at the injection site,  the dorsolat-
eral prostate.  In addition,  there was no eﬀect of 
Ad-REIC treatment on hematological parameters or 
spleen weight.  It therefore seems that Ad-REIC and 
the gene product,  secreted REIC protein,  do not 
induce serious systemic toxicity or non-speciﬁc inﬂam-
mation under the indicated conditions.
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　 The second step of our work was to analyze the 
local side eﬀects associated with an intra-prostatic 
delivery of the Ad-REIC vector by direct injection.  
To investigate the probable local toxicity due to the 
adenovirus or the gene products,  including the 
secreted REIC protein,  we examined the histopatho-
logical changes of the dorsolateral prostate after the 
Ad-mREIC injection.  We could not detect any histo-
logical damage to the prostate gland after PBS or 
Ad-REIC treatment.  In the Ad-LacZ group,  there was 
some damage to the prostate gland,  which may have 
been due to the toxicological proﬁle of the adenoviral 
vectors [26].  The lack of local toxicity in the 
Ad-mREIC-injected prostate glands was consistent 
with the previous reports showing that Ad-hREIC 
induces cytotoxic or apoptotic eﬀects only in cancer 
cells and not in normal cells [8,  11].  As for the 
lymphocyte inﬁltration in the prostatic interstitial 
space,  the phenomenon was observed in both the 
Ad-LacZ and Ad-mREIC treatment groups.  It is 
likely that the adenoviral vector may have caused the 
inﬂammatory reaction.  In addition,  a recent study 
reported that the REIC protein induced a chemokine-
like action that caused the accumulation of immune 
cells when directly injected into subcutaneous tumors 
in C57BL/6 mice [14].  Thus,  the other possibility is 
that the gene product,  the REIC protein,  might have 
been involved in lymphocyte inﬁltration in the 
Ad-mREIC-treated group.  Further studies will clarify 
the mechanisms of the Ad-REIC-induced immunomod-
ulatory eﬀects in locally injected normal and tumor 
tissues.
　 Our results show that the adenoviral vector encod-
ing the REIC/Dkk-3 gene and the CAG promoter has 
no signiﬁcant toxicity and is therapeutically eﬀective 
when directly injected into the tumors of mice with 
experimental prostate cancer or into the prostates of 
normal mice at the indicated doses.  We believe that 
the current study provides valuable information for 
future clinical trials of Ad-REIC-mediated gene ther-
apy against human prostate cancer.
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